Cargando…
A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS)
ENMD-2076, an aurora-A kinase inhibitor with anti-angiogenic properties, has shown activity in solid and hematologic malignancies. We investigated oral ENMD-2076 in an open-label, single-arm phase II study using 275 mg daily on a 28-day cycle in patients with advanced soft-tissue sarcomas (STS) rece...
Autores principales: | Veitch, Zachary, Zer, Alona, Loong, Herbert, Salah, Samer, Masood, Maryam, Gupta, Abha, Bradbury, Penelope A., Hogg, David, Wong, Andrew, Kandel, Rita, Charames, George S., Abdul Razak, Albiruni R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517396/ https://www.ncbi.nlm.nih.gov/pubmed/31089155 http://dx.doi.org/10.1038/s41598-019-43222-6 |
Ejemplares similares
-
Selected by gene co-expression network and molecular docking analyses, ENMD-2076 is highly effective in glioblastoma-bearing rats
por: Zhong, Sheng, et al.
Publicado: (2019) -
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer
por: Diamond, Jennifer R., et al.
Publicado: (2018) -
Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer
por: Ionkina, Anastasia A., et al.
Publicado: (2017) -
Clinical outcomes of non‐osteogenic, non‐Ewing soft‐tissue sarcoma of bone––experience of the Toronto Sarcoma Program
por: Veitch, Zachary W., et al.
Publicado: (2020) -
Primary cardiac sarcomas: A multi‐national retrospective review
por: Chen, Tom Wei‐Wu, et al.
Publicado: (2018)